Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

MRKR Marker Therapeutics

Watchlist
0.345
-0.012-3.39%
Close 09/23 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
0.360
Open
0.350
Turnover
40.78K
Low
0.334
Pre Close
0.357
Volume
117.06K
Market Cap
28.85M
P/E(TTM)
Loss
52wk High
1.730
Shares
83.60M
P/E(Static)
Loss
52wk Low
0.250
Float Cap
20.63M
Bid/Ask %
66.67%
Historical High
244.800
Shs Float
59.78M
Volume Ratio
0.47
Historical Low
0.074
Dividend TTM
--
Div Yield TTM
250
P/B
1.03
Dividend LFY
--
Div Yield LFY
72442.77%
Turnover Ratio
0.20%
Amplitude
7.22%
Avg Price
0.348
Lot Size
1
Float Cap
20.63M
Bid/Ask %
66.67%
Historical High
244.800
Shs Float
59.78M
Volume Ratio
0.47
Historical Low
0.074
Dividend TTM
--
P/B
1.03
Dividend LFY
--
Turnover Ratio
0.20%
Amplitude
7.22%
Avg Price
0.348
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
CEO: Hoang MBA, Peter L.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top